Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

NCT02594371 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Oraxol
DRUG: IV paclitaxel

Sponsor

Athenex, Inc.